Lila Hope

Partner at Cooley

Speaker

Lila is a partner in Cooley’s life sciences transactional group and co-chair of the firm’s Women’s Initiative. For 20+ years, she has focused on the representation of life sciences companies discovering, developing, and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships and platform discovery and option deals. In addition, she counsels clients’ management, operational and legal teams on day-to-day matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She also is routinely involved in the evaluation of a company’s product rights and operational risks in support of financing, public offering and M&A transactions. In addition to her long-established practice in the US, Lila maintains an active practice in cross-border licensing transactions, and she has concluded more than 35 transactions involving Asian biotechnology companies since 2015.

In 2023, Lila’s representative cross-border transactions include license and collaborations between Zion and Roche, Rona and KeyMed, Zhimeng and GSK, and Impact and Eikon. She also led or co-led multiple ADC-related transactions in 2023, including transactions between MediLink and Zai Lab, MediLink and BioNTech, and SystImmune and Bristol-Myers Squibb.

Lila has been recognized by Chambers USA in the category of Life Sciences: Corporate/Commercial – California in its 2020 – 2023 editions, and she has been ranked by The Legal 500 as a key lawyer in the Healthcare: Life Sciences category. She also is frequently sought out as a speaker and moderator at conferences and forums in the US and in China.